Myriad Genetics (NASDAQ:MYGN) was downgraded by research analysts at ValuEngine from a “buy” rating to a “hold” rating in a research report issued on Thursday.

MYGN has been the topic of a number of other research reports. Barclays lifted their price target on shares of Myriad Genetics from $35.00 to $38.00 and gave the company an “equal weight” rating in a report on Wednesday, August 22nd. Zacks Investment Research lowered shares of Myriad Genetics from a “buy” rating to a “hold” rating in a report on Monday, October 29th. Deutsche Bank lifted their price target on shares of Myriad Genetics from $37.00 to $43.00 and gave the company a “hold” rating in a report on Monday, November 5th. Piper Jaffray Companies upgraded shares of Myriad Genetics from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $38.00 to $53.00 in a report on Wednesday, October 10th. Finally, BidaskClub lowered shares of Myriad Genetics from a “buy” rating to a “hold” rating in a report on Saturday, November 3rd. Three equities research analysts have rated the stock with a sell rating, five have given a hold rating and four have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $41.90.

MYGN stock opened at $30.85 on Thursday. The company has a market capitalization of $2.45 billion, a price-to-earnings ratio of 24.31, a PEG ratio of 2.02 and a beta of 0.51. The company has a debt-to-equity ratio of 0.23, a current ratio of 3.17 and a quick ratio of 2.86. Myriad Genetics has a one year low of $27.27 and a one year high of $50.44.

Myriad Genetics (NASDAQ:MYGN) last released its earnings results on Tuesday, November 6th. The company reported $0.43 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.30 by $0.13. The firm had revenue of $202.30 million during the quarter, compared to analysts’ expectations of $203.20 million. Myriad Genetics had a net margin of 7.07% and a return on equity of 10.07%. Myriad Genetics’s revenue for the quarter was up 13.1% on a year-over-year basis. During the same period in the previous year, the company earned $0.26 EPS. As a group, sell-side analysts expect that Myriad Genetics will post 1.43 EPS for the current year.

Several institutional investors and hedge funds have recently made changes to their positions in the business. FMR LLC lifted its holdings in shares of Myriad Genetics by 409.3% during the 3rd quarter. FMR LLC now owns 215,441 shares of the company’s stock valued at $9,910,000 after acquiring an additional 173,141 shares in the last quarter. Rafferty Asset Management LLC acquired a new position in shares of Myriad Genetics during the 3rd quarter valued at $806,000. American International Group Inc. lifted its holdings in shares of Myriad Genetics by 3.3% during the 3rd quarter. American International Group Inc. now owns 52,744 shares of the company’s stock valued at $2,426,000 after acquiring an additional 1,684 shares in the last quarter. BlackRock Inc. lifted its holdings in shares of Myriad Genetics by 3.5% during the 3rd quarter. BlackRock Inc. now owns 11,466,610 shares of the company’s stock valued at $527,464,000 after acquiring an additional 383,089 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in shares of Myriad Genetics by 6.6% during the 3rd quarter. Bank of New York Mellon Corp now owns 910,032 shares of the company’s stock valued at $41,861,000 after acquiring an additional 55,974 shares in the last quarter. Institutional investors own 96.75% of the company’s stock.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.

Featured Story: Fiduciary

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.